SSA
NRIX icon

Schonfeld Strategic Advisors’s Nurix Therapeutics NRIX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-52,340
Closed -$596K – 2449
2025
Q2 		$596K Sell
52,340
-6,012
-10% -$65K ﹤0.01% 1490
2025
Q1 		$693K Sell
58,352
-344,603
-86% -$5.76M ﹤0.01% 1443
2024
Q4 		$7.59M Buy
402,955
+47,353
+13% +$1.09M 0.04% 380
2024
Q3 		$7.99M Sell
355,602
-76,687
-18% -$1.74M 0.05% 364
2024
Q2 		$9.02M Buy
432,289
+170,127
+65% +$2.65M 0.06% 377
2024
Q1 		$3.85M Buy
+262,162
New +$2.82M 0.03% 740
2022
Q1 		– Sell
-7,600
Closed -$220K – 2808
2021
Q4 		$220K Buy
+7,600
New +$230K ﹤0.01% 1681

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schonfeld Strategic Advisors's NRIX Position: Q3 2025 in Review

Schonfeld Strategic Advisors sold out of Nurix Therapeutics (NRIX) in Q3 2025, closing a stake of 52,340 shares — an estimated $596K sold.

Schonfeld Strategic Advisors first reported a position in NRIX in Q4 2021 and held it in 7 quarters. The position peaked at $9.02M in Q2 2024. 173 funds tracked by Wall St. Rank hold NRIX as of Q3 2025.

  • Schonfeld Strategic Advisors reported no remaining Nurix Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 52,340 Nurix Therapeutics shares in Q3 2025, an estimated $596K.
  • Schonfeld Strategic Advisors first reported a position in Nurix Therapeutics in Q4 2021 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's Nurix Therapeutics position peaked at $9.02M in Q2 2024.
  • 173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.